Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Prostatic Neoplasms × Nivolumab × Clear all

Phase

Phase 2 13 Phase 1/2 6 Phase 1 5 Phase 3 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 21 Melanoma 20 Carcinoma, Renal Cell 12 Stomach Neoplasms 8 Lung Neoplasms 8 Squamous Cell Carcinoma of Head and Neck 5 Brain Neoplasms 5 Mesothelioma 4 Kidney Neoplasms 4 Carcinoma, Hepatocellular 4 Adenocarcinoma Of Esophagus 4 Urinary Bladder Neoplasms 3 Neoplasms 3 Neoplasm Metastasis 3 Head and Neck Neoplasms 3 Various Advanced Cancer 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Mesothelioma, Malignant 2 Liver Neoplasms 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Carcinoma 2 Anus Neoplasms 2 Adenocarcinoma 2 von Hippel-Lindau Disease 1 Uveal Melanoma 1 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Thoracic Neoplasms 1

Interventions

Docetaxel 43 Prednisone 42 Radiotherapy 41 Goserelin 39 Leuprolide 37 bicalutamide 35 enzalutamide 25 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 24 Androgen Antagonists 22 Flutamide 19 Triptorelin Pamoate 17 apalutamide 15 Zoledronic Acid 12 Gonadotropin-Releasing Hormone 12 Abiraterone Acetate 12 gallium 68 PSMA-11 11 abiraterone 11 Radiation 11 Magnetic Resonance Spectroscopy 11 Prednisolone 9 Estramustine 8 Dexamethasone 8 Specimen Handling 7 Chemotherapy, Adjuvant 7 Buserelin 7 orteronel 6 luprolide acetate gel depot 6 darolutamide 6 cabazitaxel 6 Standard of Care 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04100018 2025-06-12

CheckMate 7DX

Bristol-Myers Squibb

Phase 3 Completed

1,030 enrolled 25 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡